A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.
Newly analyzed data revealed eight gene loci associated with testicular cancer risk that were not previously known.
Circulating tumor DNA blood tests can rapidly identify treatment-targetable tumor mutations in patients diagnosed with non–small-cell lung cancer.
Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy regimens failed to prolong overall survival in lung and breast cancers.
Kinase oncoproteins and growth factors both activate the proto-oncogene c-FOS and DUSP1, allowing the persistence of residual leukemia cell populations despite tyrosine kinase inhibitor therapy.
Unmutated immunoglobulin heavy chain variable region gene (IGHV) status does not adversely impact survival among ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.
ERBB2/HER2 mutations appear to be rare but targetable oncogenic drivers in non-small cell lung cancer, according to findings from a small retrospective cohort records analysis.
An IHC assay for ALK status in non-small cell lung cancer tumor tissue predicts crizotinib treatment outcomes and offers a rapid and potentially less expensive alternative to older FISH ALK status assays.
Despite significant toxicities, idelalisib improved time to progression for patients with treatment-resistant chronic lymphocytic leukemia.